LYN kinase activators for use in treating fibrosis or diseases associated with fibrosis

Lyn kinase activators are used to treat fibrosis and related diseases by reducing monocyte and myofibroblast counts and modulating cytokine/chemokine levels, addressing the limitations of existing treatments.

WO2026125941A1PCT designated stage Publication Date: 2026-06-18BIODEXA LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
BIODEXA LTD
Filing Date
2025-12-12
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current treatments for fibrosis and monocyte-driven diseases such as Langerhans cell histiocytosis, Hemophagocytic lymphohistiocytosis, and Erdheim-Chester Disease are inadequate, particularly due to the irreversible nature of fibrosis and the role of monocytes in their pathogenesis.

⚗Method used

Administering a therapeutically effective amount of a Lyn kinase activator to decrease monocyte and myofibroblast numbers and modulate cytokine and chemokine secretion, thereby targeting the underlying pathogenic mechanisms of fibrosis and associated diseases.

🎯Benefits of technology

The Lyn kinase activator effectively reduces monocyte and myofibroblast counts by 5-75% and modulates cytokine and chemokine levels, providing therapeutic benefits for fibrosis and associated autoimmune and inflammatory disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2025000644_18062026_PF_FP_ABST
    Figure IB2025000644_18062026_PF_FP_ABST
Patent Text Reader

Abstract

Methods for treating a monocyte-driven disease (such as fibrosis) with a Lyn kinase activator are provided. Also provided are methods of slowing fibrosis progression in a subject by administering to the subject a therapeutically effective amount of a Lyn kinase activator.
Need to check novelty before this filing date? Find Prior Art